Establishment Licensing Fees (Veterinary Drugs) Regulations (SOR/98-4)

Regulations are current to 2017-11-20 and last amended on 2011-04-01. Previous Versions

Establishment Licensing Fees (Veterinary Drugs) Regulations

SOR/98-4

FINANCIAL ADMINISTRATION ACT

Registration 1997-12-17

Establishment Licensing Fees (Veterinary Drugs) Regulations

P.C. 1997-1896 1997-12-17

His Excellency the Governor General in Council, on the recommendation of the Minister of Health and the Treasury Board, pursuant to paragraph 19.1(a)Footnote a of the Financial Administration Act and, considering that it is in the public interest to remit certain debts, pursuant to subsection 23(2.1)Footnote b of that Act, hereby makes the annexed Establishment Licensing Fees Regulations (1056).

Interpretation

Marginal note:Definitions
  •  (1) The definitions in this subsection apply in these Regulations.

    activity

    activité

    activity means an activity set out in Table I to section C.01A.008 of the Food and Drug Regulations. (activité)

    category

    catégorie

    category means a category of drugs set out in Table II to section C.01A.008 of the Food and Drug Regulations. (catégorie)

    drug

    drogue

    drug has the same meaning as in subsection C.01A.001(2) of the Food and Drug Regulations. (drogue)

    establishment licence

    licence d’établissement

    establishment licence means a licence issued under section C.01A.008 of the Food and Drug Regulations. (licence d’établissement)

    site

    site

    site means

    • (a) a building specified in an establishment licence and located more than one kilometre from any other building specified in the licence; or

    • (b) more than one building specified in an establishment licence, all of which are located within one kilometre of each other. (site)

  • Marginal note:Other words and expressions

    (2) Unless the context otherwise requires, all other words and expressions used in these Regulations have the meanings assigned to them by the Food and Drugs Act, the Food and Drug Regulations, the Controlled Drugs and Substances Act or the Narcotic Control Regulations, as the case may be.

Application

Marginal note:Application

 These Regulations apply only to establishment licences for activities that relate to drugs for veterinary use only.

  • SOR/2011-84, s. 2.

Fees

Marginal note:Amount payable

 The fee that is payable for an establishment licence is the sum of the fees referred to in sections 4 to 10, as applicable.

Marginal note:Licence authorizing fabrication
  •  (1) The fee payable for each site at which one or more activities is authorized by the establishment licence including the fabrication of drugs is the basic fee, set out in column 2 of item 1 of Schedule 1, together with each of the following fees that are applicable:

    • (a) if the licence is in respect of more than one category of drugs, the fee set out in column 2 of item 2 of Schedule 1, for each additional category;

    • (b) if the licence is in respect of more than one dosage form class, the applicable fee set out in column 2 of item 3 of Schedule 1; and

    • (c) if the licence is in respect of sterile dosage forms, the fee set out in column 2 of item 4 of Schedule 1.

  • Marginal note:Importing

    (2) Despite section 6, if importing is authorized by the establishment licence at a site referred to in subsection (1), the fee referred to in paragraph 6(b) is also payable.

Marginal note:Licence authorizing packaging/labelling
  •  (1) The fee that is payable for each site at which one or more activities is authorized by the establishment licence, including packaging/labelling drugs but not including fabricating drugs, is the basic fee, set out in column 2 of item 1 of Schedule 2, together with each of the following fees that are applicable:

    • (a) if the licence is in respect of more than one category of drugs, the fee set out in column 2 of item 2 of Schedule 2, for each additional category; and

    • (b) if the licence is in respect of more than one dosage form class, the applicable fee set out in column 2 of item 3 of Schedule 2.

  • Marginal note:Importing

    (2) Despite section 6, if importing is authorized by the establishment licence at a site referred to in subsection (1), the fee referred to in paragraph 6(b) is also payable.

Marginal note:Licence authorizing importation

 The fee that is payable for one or more activities authorized by the establishment licence, including importing drugs but not including fabricating or packaging/labelling drugs, is

  • (a) for each site where those activities are so authorized, the basic fee, set out in column 2 of item 1 of Schedule 3, together with each of the following fees that are applicable:

    • (i) if the licence is in respect of more than one category of drugs, the fee set out in column 2 of item 2 of Schedule 3, for each additional category, and

    • (ii) if the licence is in respect of more than one dosage form class, the applicable fee set out in column 2 of item 3 of Schedule 3; and

  • (b) for each fabricator outside Canada of drugs that are imported, except where a certificate from a Canadian inspector indicating that the fabricator’s buildings, equipment, practices and procedures meet the applicable requirements of Divisions 2 to 4 of Part C of the Food and Drug Regulations is provided by the importer, the sum of the following fees that are applicable:

    • (i) the fee set out in column 2 of item 4 of Schedule 3, and

    • (ii) if the licence is in respect of more than one dosage form class, for each additional dosage form class, the fee set out in column 2 of item 5 of Schedule 3.

Marginal note:Licence authorizing distribution

 The fee that is payable for each site at which one or more activities is authorized by the establishment licence, including distributing drugs as a distributor referred to in paragraph C.01A.003(b) of the Food and Drug Regulations but not including fabricating, packaging/labelling or importing drugs, is the basic fee, set out in column 2 of item 1 of Schedule 3, together with each of the following fees that are applicable:

  • (a) if the licence is in respect of more than one category of drugs, the fee set out in column 2 of item 2 of Schedule 3, for each additional category; and

  • (b) if the licence is in respect of more than one dosage form class, the applicable fee set out in column 2 of item 3 of Schedule 3.

Marginal note:Drug analysis fee

 In addition to the fees referred to in sections 4 to 7, the fee that is payable, if an establishment licence authorizes the holder to fabricate, package/label, import or distribute drugs as a distributor referred to in paragraph C.01A.003(b) of the Food and Drug Regulations, is for any of those activities, the highest fee set out in column 2 of Schedule 4 that corresponds to drugs described in column 1 of that Schedule

  • (a) in respect of which the licence is requested; and

  • (b) except in the case of an importer, for which the holder of the licence has obtained an identification number (DIN) or a numbered certificate of registration (GP).

Marginal note:Licence authorizing distribution or wholesaling

 The fee that is payable for each site at which one or more activities is authorized by the establishment licence, including distributing drugs as a distributor referred to in paragraph C.01A.003(a) of the Food and Drug Regulations or wholesaling drugs but not including fabricating, packaging/labelling or importing drugs or distributing drugs as a distributor referred to in paragraph C.01A.003(b) of those Regulations, is a basic fee of $1,500.

Marginal note:Licence authorizing testing

 The fee that is payable for each site at which only the testing of drugs is authorized by the establishment licence is a basic fee of $1,000.

Marginal note:Remission
  •  (1) Subject to subsection 13(2), if the total of the fees payable under sections 3 to 10 of these Regulations and the fee payable under section 3 of the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations is greater than an amount equal to 1.5% of the applicant’s actual gross revenue from the sale, testing and packaging/labelling of drugs, as well as controlled drugs and narcotics not in dosage form, for the previous calendar year, remission is granted of the difference between those amounts if the applicant provides, with their application for the annual review of their licence, a statement signed by the individual responsible for the applicant’s financial affairs that sets out the actual gross revenue.

  • Marginal note:Statement — first year of activities

    (2) If the applicant has not completed their first calendar year of conducting activities under the licence, the applicant shall provide the statement within 90 days after the day on which that year ends in order to be eligible for the remission.

  • SOR/2011-84, s. 3.
Marginal note:Timing of payment
  •  (1) Subject to subsection (2), the fee is payable on the day on which the establishment licence is issued or the application for the annual review of the licence is submitted.

  • Marginal note:Timing of deferred payment

    (2) In the case of an applicant referred to in subsection 11(2), the fee for an application for the annual review of their licence is payable upon the expiry of the 90–day period.

  • SOR/2011-84, s. 3.
Marginal note:Audited records
  •  (1) If the Minister determines that, on the basis of any information available to the Minister, the statement provided under subsection 11(1) is not adequate to determine the actual gross revenue referred to in that subsection, the Minister may require, for the purpose of determining the fee payable or the amount of the remission, the applicant to provide sales records that have been audited by a qualified independent auditor.

  • Marginal note:Omission

    (2) If the applicant fails to provide the Minister with the audited sales records within 90 days after the day on which the Minister requested those records, the difference between the fee and the amount already paid is immediately payable.

  • Marginal note:Difference payable

    (3) If the audited sales records establish that the amount already paid is less than the amount payable, the difference between those amounts is immediately payable.

  • Marginal note:Difference remitted

    (4) If the audited sales records establish that the amount already paid is greater than the amount payable, remission is granted of an amount equal to the difference between those amounts, which the Minister must repay to the applicant.

  • SOR/2011-84, s. 3.

 [Repealed, SOR/2011-84, s. 3]

 [Repealed, SOR/2011-84, s. 3]

Licence Amendments

Marginal note:Amendment to add sterile dosage forms

 If an establishment licence authorizing the holder to carry out one or more activities including fabricating drugs is amended to authorize sterile dosage forms of drugs for the first time at a site, the fee payable for each site at which those forms are so authorized is the basic fee set out in column 2 of item 1 of Schedule 1.

Marginal note:Amendment to add activity
  •  (1) If an establishment licence is amended to add an activity at a site, the fee payable for the amendment to the licence is, for each site at which the activity is added,

    • (a) if the amendment authorizes the holder to fabricate drugs, the basic fee set out in column 2 of item 1 of Schedule 1;

    • (b) if the amendment authorizes the holder to package/label drugs but the amended licence does not authorize the holder to fabricate drugs, the basic fee set out in column 2 of item 1 of Schedule 2;

    • (c) if the amendment authorizes the holder to import drugs but the amended licence does not authorize the holder to fabricate or package/label drugs, the basic fee set out in column 2 of item 1 of Schedule 3;

    • (d) if the amendment authorizes the holder to distribute drugs as a distributor referred to in paragraph C.01A.003(b) of the Food and Drug Regulations, but the amended licence does not authorize the holder to fabricate, package/label or import drugs, the basic fee set out in column 2 of item 1 of Schedule 3; and

    • (e) if the amendment authorizes the holder to distribute drugs as a distributor referred to in paragraph C.01A.003(a) of the Food and Drug Regulations, or to wholesale drugs or to carry out both activities, but the amended licence does not authorize the holder to fabricate, package/label or import drugs or distribute drugs as a distributor referred to in paragraph C.01A.003(b) of those Regulations, the basic fee set out in section 9.

  • Marginal note:Amendment to add category

    (2) Subject to subsection (3), if an establishment licence is amended to add a category of drugs for an activity that is authorized by the licence at a site, the fee payable for the amendment to the licence is, for each site at which the category of drugs is added for the authorized activity,

    • (a) if the amendment authorizes the holder to fabricate an additional category of drugs, the basic fee set out in column 2 of item 1 of Schedule 1;

    • (b) if the amendment authorizes the holder to package/label an additional category of drugs, the basic fee set out in column 2 of item 1 of Schedule 2;

    • (c) if the amendment authorizes the holder to import an additional category of drugs, the basic fee set out in column 2 of item 1 of Schedule 3;

    • (d) if the amendment authorizes the holder to distribute an additional category of drugs as a distributor referred to in paragraph C.01A.003(b) of the Food and Drug Regulations, the basic fee set out in column 2 of item 1 of Schedule 3;

    • (e) if the amendment authorizes the holder to distribute an additional category of drugs as a distributor referred to in paragraph C.01A.003(a) of the Food and Drug Regulations, or to wholesale an additional category of drugs, the basic fee set out in section 9; and

    • (f) if the amendment authorizes the holder to test an additional category of drugs, the basic fee set out in section 10.

  • Marginal note:Included categories

    (3) If an establishment licence is amended to add a category of drugs in respect of more than one activity referred to in paragraphs (2)(a) to (f), the fee payable under subsection (2) is the highest applicable fee for those activities.

Marginal note:Fee exemption

 If a remission has been granted under section 11 or 13, no fee is payable under section 16 or 17 for the amendment of the establishment licence.

  • SOR/2011-84, s. 4.
Marginal note:Time of payment

 The fees determined in accordance with sections 16 and 17 are payable on the day on which the amended licence is issued.

Suspended Licences

Marginal note:Fee for reinstated licence
  •  (1) Subject to subsection (2), if an establishment licence has been suspended by the Minister of Health in respect of any or all matters indicated in subsection C.01A.008(2) of the Food and Drug Regulations, the fee payable for a reinstated licence is

    • (a) if it authorizes the holder to carry out one or more activities, including fabricating drugs, for each site in respect of which the matter is reinstated, the basic fee set out in column 2 of item 1 of Schedule 1;

    • (b) if it authorizes the holder to carry out one or more activities, including packaging/labelling drugs but not including fabricating drugs, for each site in respect of which the matter is reinstated, the basic fee set out in column 2 of item 1 of Schedule 2;

    • (c) if it authorizes the holder to carry out one or more activities, including importing drugs but not including fabricating or packaging/labelling drugs, for each site in respect of which the matter is reinstated, the basic fee set out in column 2 of item 1 of Schedule 3;

    • (d) if it authorizes the holder to carry out one or more activities, including distributing drugs as a distributor referred to in paragraph C.01A.003(b) of the Food and Drug Regulations, but not including fabricating, packaging/labelling or importing drugs, for each site in respect of which the matter is reinstated, the basic fee set out in column 2 of item 1 of Schedule 3;

    • (e) if it authorizes the holder to carry out one or more activities, including distributing drugs as a distributor referred to in paragraph C.01A.003(a) of the Food and Drug Regulations or wholesaling drugs but not including fabricating, packaging/labelling or importing drugs or distributing drugs as a distributor referred to in paragraph C.01A.003(b) of those Regulations, for each site in respect of which the matter is reinstated, the basic fee set out in section 9; and

    • (f) if it authorizes the holder only to test drugs, for each site in respect of which the matter is reinstated, the basic fee set out in section 10.

  • Marginal note:Remission

    (2) If a remission has been granted under section 11 or 13, the fee payable for a reinstated establishment licence is the lesser of

    • (a) the fee determined in accordance with section 11 or 13, and

    • (b) the fee determined in accordance with subsection (1).

  • Marginal note:Time of payment

    (3) The fee determined in accordance with this section is payable on the day on which the establishment licence is reinstated.

  • SOR/2011-84, s. 5.

Transitional Provisions

Marginal note:Licence issued before coming into force

 Despite section 11, the fees determined in accordance with sections 3 to 10 and subsection 13(2) are payable on January 1, 1998, if an establishment licence is issued before that date.

Marginal note:Application for a reduction
  •  (1) Despite subsection 12(2), if an application for an establishment licence is submitted before January 1, 1998, an application for a fee reduction may be submitted no later than 60 days after the day of the coming into force of these Regulations.

  • Marginal note:Remission

    (2) If a person has paid the total fee referred to in subsection 12(1) at the time an application for a fee reduction is submitted within the period referred to in subsection (1), the Minister of Health shall grant a remission to the applicant of an amount equal to the difference between

    • (a) in the case of an application under section 13, an amount equal to the difference between

      • (i) the sum of the fees paid pursuant to subsection 12(1), and

      • (ii) the total fee payable pursuant to subsection 13(2); and

    • (b) in the case of an application under section 14, an amount equal to the difference between

      • (i) the sum of the fees paid pursuant to subsection 12(1), and

      • (ii) the sum of the fees payable pursuant to paragraph 14(3)(a).

Coming into Force

Marginal note:Coming into force

 These Regulations come into force on January 1, 1998.

SCHEDULE 1(Sections 4, 16, 17 and 20)

Column 1Column 2
ItemDescriptionFee ($)
1Basic fee6,000
2Each additional category1,500
3Dosage form classes:
3,000
6,000
7,500
9,000
10,500
  • (f) each additional class

600
4Sterile dosage forms3,000

SCHEDULE 2(Sections 5, 17 and 20)

Column 1Column 2
ItemDescriptionFee ($)
1Basic fee4,000
2Each additional category1,000
3Dosage form classes:
2,000
  • (b) 3 or more classes

3,000

SCHEDULE 3(Sections 6, 7, 17 and 20)

Column 1Column 2
ItemDescriptionFee ($)
1Basic fee2,500
2Each additional category625
3Dosage form classes:
1,250
  • (b) 3 or more classes

2,500
4Each fabricator600
5Each additional dosage form class for each fabricator300

SCHEDULE 4(Section 8)

Column 1Column 2
ItemDescriptionFee ($)
1. to 4.[Repealed, SOR/2011-84, s. 6]
5Drugs for veterinary use250
6. to 11.[Repealed, SOR/2011-84, s. 7]
  • SOR/2011-84, ss. 6, 7.

AMENDMENTS NOT IN FORCE

  • — SOR/2017-77, s. 1

    • 1 Section 2 of the Establishment Licensing Fees (Veterinary Drugs) RegulationsFootnote 1 is replaced by the following:

      • Application

        2 These Regulations apply to establishment licences for activities that relate to drugs for veterinary use only, with the exception of those for activities that relate to any active pharmaceutical ingredient, as defined in subsection C.01A.001(1) of the Food and Drug Regulations, that is for veterinary use.

  • — SOR/2017-77, s. 2

    • 2 Subsection 11(1) of the French version of the Regulations is replaced by the following:

      • Remise
        • 11 (1) Sous réserve du paragraphe 13(2), si le total du prix à payer selon les articles 3 à 10 du présent règlement et du prix à payer selon l’article 3 du Règlement sur les prix à payer pour les licences de distributeurs autorisés de drogues contrôlées et de stupéfiants (usage vétérinaire) est supérieur à un montant correspondant à 1,5 % des recettes brutes réelles du demandeur pour l’année civile précédente qui proviennent de la vente, de l’analyse et de l’emballage-étiquetage de drogues — ainsi que de drogues contrôlées et de stupéfiants qui ne sont pas sous forme posologique — et si le demandeur fournit avec la demande d’examen annuel de sa licence un état de ces recettes dûment signé par son responsable des affaires financières, remise est accordée d’une somme égale à la différence entre ce prix total et ce montant.

Date modified: